SCIENMAG: Medicine & Health

JANUARY 16, 2024

SA is often harmless, but it is also a leading cause of hospital-acquired and community-associated infections. A vaccine for SA would be a game-changer for public health, but for decades, all vaccine candidates for […]

Vaccine 72

Vaccine Hospitals 72

Eye on FDA

NOVEMBER 17, 2020

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

Vaccine 81

Vaccine FDA Hospitals International 81

The Pharma Data

APRIL 20, 2022

Results of a new multicenter study published in the New England Journal of Medicine found that vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine reduced the risk of COVID-19-associated hospitalizations in children ages 5-11 years by two-thirds during the Omicron period.

Vaccine 52

Vaccine Hospitals Research Disease 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — The COVID-19 vaccine rollout is meeting resistance as many health care workers are refusing shots, the Associated Press reported Friday. It is occurring in nursing homes and to some degree in hospitals, with employees expressing fears of side effects. FRIDAY, Jan. Associated Press Article. © 2021 HealthDay.

Vaccine 52

Vaccine Nurses Hospitals Science 52

The Pharma Data

JANUARY 29, 2021

EU Regulator Approves Oxford-AstraZeneca COVID-19 Vaccine. 29, 2021 — European Union regulators have authorized the AstraZeneca COVID-19 vaccine for use in adults, CBS News reported Friday. The move comes after the European Medicines Agency has been criticized for not moving fast enough to vaccinate its population.

Regulations 52

Regulations Vaccine Clinical Trials Hospitals 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. ” Can the vaccines make you sick? Once vaccinated, can I get rid of the masks?

Vaccine 52

Vaccine Virus DNA Doctors 52

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. mRNA vaccines include the Pfizer-BioNTech Comirnaty vaccine and the Moderna Spikevax vaccine.

Immune Response 52

Immune Response Vaccine Hospitals Laboratories 52

The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

JANUARY 21, 2021

21, 2021 — Despite scattered media reports of severe allergic reactions to the Pfizer COVID-19 vaccine, a detailed analysis shows that such incidents are very rare, striking just 11 people for every million doses given. Tom Shimabukuro tracked data on reactions to the Pfizer vaccine soon after it was approved in December.

Vaccine 52

Vaccine Hospitals Disease Research 52

The Pharma Data

SEPTEMBER 5, 2021

million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines. “The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. million for the first dose of either mRNA vaccine and 5.7 The total number of people evaluated was 6.2

Vaccine 52

Vaccine Clinical Trials Research Virus 52

The Pharma Data

OCTOBER 6, 2021

First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older Timely new data for the start of the influenza vaccination campaigns across the Northern Hemisphere. About the study.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

MARCH 5, 2021

Novartis announced today that it has signed an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from CureVac to aid in the fight against the COVID-19 pandemic. Preparations for the start of production, technology transfer and test runs are already underway. Disclaimer.

Vaccine 52

Vaccine Production Biosimilars Hospitals 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 15, 2021

15, 2021 (American Heart Association News) — Experts have a simple answer for heart and stroke patients questioning whether they need a COVID-19 vaccination. The Food and Drug Administration-approved vaccines pose no special problems for such patients, said Elkind, who also is president of the American Heart Association.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

DECEMBER 8, 2020

AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 The University of Oxford claims no vaccinated participants were hospitalized or suffered serious forms of the disease.

Vaccine 52

Vaccine Trials Hospitals Disease 52

The Pharma Data

JANUARY 14, 2021

14, 2021 — Folks who’ve gotten through a COVID-19 infection might naturally question whether they need to get a coronavirus vaccination when their turn comes. Twenty-five COVID patients were involved in the study, including nine with severe or moderate disease that required hospitalization. THURSDAY, Jan.

Vaccine 52

Vaccine Trials Virus Hospitals 52

The Pharma Data

MARCH 2, 2021

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. “For

Vaccine 52

Vaccine Clinical Trials FDA Licensing 52

The Pharma Data

JUNE 17, 2022

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young children ages 6 months through 4 years in Phase 2/3 clinical trial Pfizer-BioNTech COVID-19 Vaccine now authorized in the U.S. Ugur Sahin, M.D.,

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

AUGUST 16, 2021

Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable.

Vaccine 52

Vaccine FDA Virus Immune Response 52

Broad Institute

OCTOBER 16, 2024

William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines By Corie Lok October 16, 2024 Breadcrumb Home F. His T7 expression technology can be used to make large quantities of nearly any RNA or protein.

Vaccine 64

Vaccine RNA Laboratories Molecular Biology 64

The Pharma Data

MARCH 16, 2022

• Submission based on real-world safety and efficacy data from Israel • Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who received an additional booster dose of Pfizer-BioNTech COVID-19 Vaccine compared to individuals who received only an initial booster.

Vaccine 52

Vaccine Small Molecule FDA Disease 52

The Pharma Data

DECEMBER 21, 2020

Professor Binder and her team are well-recognized experts who will increase our understanding of UV1’s mechanism of action and contribute data on anti-tumor activity induced by UV1 vaccination.”. About UV1 UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Vaccine 52

Vaccine Trials Clinical Trials Clinical Development 52

The Pharma Data

JANUARY 24, 2021

We have no choice but to keep up public health measures until vaccine-induced immunity grows substantially.”. Continued monitoring of seroprevalence will be foundational data to understanding national immunity as vaccination rolls out,” she continues. Most growth in the Prairies and Western Canada. This is vital information.

Vaccine 52

Vaccine Government Virus Hospitals 52

Drugs.com

MARCH 6, 2025

THURSDAY, March 6, 2025 -- The antiviral drug Paxlovid may not offer much protection against COVID-related hospitalizations or deaths for vaccinated older adults after all. Research published recently in JAMA Network Open looked at data from more.

Vaccine 343

Vaccine Hospitals Research Drugs 343

Drugs.com

AUGUST 8, 2023

8, 2023 -- Most people know that even though vaccination doesn't eliminate their risk of getting COVID-19, it does lower their odds for severe illness -- including their risk for hospitalization and death. TUESDAY, Aug. Now scientists believe they.

Hospitals 246

Hospitals Vaccine 246

Eye on FDA

DECEMBER 10, 2020

Today the Food and Drug Administration will hold a meeting of the Vaccines and Related Biologics Advisory Committee (VRBAC) to consider the application for an Emergency Use Authorization (EUA) submitted by Pfizer/BioNTech for their investigative vaccine for COVID-19. After nearly 40 years, a vaccine still eludes us.

Vaccine 97

Vaccine FDA Virus Trials 97

PLOS: DNA Science

OCTOBER 3, 2024

One of the oldest and most successful immunotherapies is simpler: a tamed version of a classic vaccine, against the infectious disease tuberculosis (TB). “BCG” is the “treatment” vaccine’s technical name, for Mycobacterium bovis Bacillus Calmette-Guérin. And every so often, tumors shrank.

Vaccine 52

Vaccine Immune Response DNA Treatment 52

The Pharma Data

DECEMBER 12, 2020

Food and Drug Administration approved Pfizer’s coronavirus vaccine for emergency use on Friday, clearing the way for the launch of a national campaign to inoculate enough Americans to stem the spread of COVID-19. ” Who is first in line to be vaccinated? SATURDAY, Dec. 12, 2020 – The U.S.

Vaccine 52

Vaccine FDA Approval FDA Nurses 52

The Pharma Data

JULY 6, 2021

Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Global Head, Janssen Research & Development, Johnson & Johnson.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccine 52

Vaccine Clinical Trials FDA Trials 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 — The Pfizer-BioNTech COVID-19 vaccine has received the first emergency use authorization (EUA) for a COVID-19 vaccine in the United States. The vaccine is administered in two doses three weeks apart. Researchers found the vaccine was 95 percent effective in preventing COVID-19. MONDAY, Dec. Redfield, M.D.,

Vaccine 52

Vaccine Nurses FDA Virus 52

The Pharma Data

MAY 7, 2021

Pfizer-BioNTech files for US approval of COVID-19 vaccine ( Reuters ) ( NYTimes ) ( Politico ) ( Press ). Covid-19 Vaccines Are Wasted as Special Syringes Run Short ( WSJ ). The US opened pandora’s box on IP waivers for Covid-19 vaccines. . In Focus: US. What happens now?

Vaccine 52

Vaccine Compounding Pharmacies Regulations Drugs 52

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 — A second COVID-19 vaccine is poised to be administered in the coming weeks after the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the Moderna COVID-19 vaccine on Friday. The EUA allows for the vaccine to be administered to adults 18 years and older in two doses one month apart.

Vaccine 52

Vaccine FDA Hospitals Disease 52

The Pharma Data

APRIL 1, 2021

Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine. Sanofi announces investment of more than €600 million to build a new vaccine facility in Toronto to increase supply of its differentiated influenza vaccines in Canada, the United States and Europe.

Vaccine 52

Vaccine Government Science Production 52